ImmunOs Therapeutics Presents Overview of Phase 1a/b Trial of Lead Compound IOS-1002
October 24, 2023 04:00 ET
|
AKAMPION
Evaluation of IOS-1002, a LILRB1 (ILT2), LILRB2 (ILT4), KIR3DL1 targeting agent, as monotherapy and in combination with pembrolizumab in advanced solid tumorsTrial overview presented at ESMO Congress...
Macomics Announces the Appointment of Kevin Lee as Independent Non-Executive Director
October 19, 2023 04:00 ET
|
Macomics Limited
EDINBURGH and CAMBRIDGE, United Kingdom, Oct. 19, 2023 (GLOBE NEWSWIRE) -- Macomics Ltd, a leader in macrophage drug discovery, announces that it has appointed Kevin Lee Ph.D., MBA as Independent...
Arvinas Gives Back to Local Greater New Haven Community in Second Annual Impact Day
October 18, 2023 07:00 ET
|
Arvinas Inc.
NEW HAVEN, Conn., Oct. 18, 2023 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
ImmunOs Therapeutics Announces Clinical Trial Collaboration with Merck & Co., Inc., Rahway, NJ, USA
October 17, 2023 04:00 ET
|
AKAMPION
- Evaluation of IOS-1002, a LILRB1 (ILT2), LILRB2 (ILT4), KIR3DL1 targeting agent, in combination with KEYTRUDA® (pembrolizumab) as part of ongoing Phase 1a/b trial in advanced solid tumors ...
Arvinas Announces Upcoming Bavdegalutamide Poster Presentation at ESMO Congress 2023
October 15, 2023 18:07 ET
|
Arvinas Inc.
NEW HAVEN, Conn., Oct. 15, 2023 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
Arvinas and Pfizer Announce Upcoming Vepdegestrant (ARV-471) Poster Presentation at ESMO Congress 2023
October 15, 2023 18:05 ET
|
Arvinas Inc.
NEW HAVEN, Conn. and NEW YORK, Oct. 15, 2023 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) and Pfizer Inc. (NYSE: PFE) today announced they will present updated Phase 1/2 data for vepdegestrant...
Oxford BioTherapeutics Relocates UK Headquarters to Strategic and Cutting-Edge R&D Location at The Oxford Science Park to Accelerate Development of its Immuno-Oncology and ADC-Based Cancer Therapies
October 11, 2023 04:00 ET
|
Oxford BioTherapeutics
Oxford, UK and San Jose, Calif., 11 October 2023 – Oxford BioTherapeutics Ltd. (OBT), a clinical stage oncology company with a pipeline of immuno-oncology and antibody-drug conjugate (ADC)-based...
IMUNON Appoints Dr. Patrick Ott to its Scientific Advisory Board
October 06, 2023 08:30 ET
|
Imunon, Inc.
Renowned Daner-Farber Cancer Institute researcher will advise on the development of IMUNON’s FixPlas™ and Indiplas™ modalities in immuno-oncology. LAWRENCEVILLE, N.J., Oct. 06, 2023 (GLOBE...
Oxford BioTherapeutics Announces Partner Boehringer Ingelheim Received U.S. FDA Fast Track Designation for BI 764532 for the Treatment of Extensive Stage Small Cell Lung Cancer and Extrapulmonary Neuroendocrine Cancers
October 03, 2023 02:00 ET
|
Oxford BioTherapeutics
BI 764532 is an investigational T-cell engager that redirects T cells towards cancer cells expressing the DLL3 proteinDLL3 was discovered using OBT’s proprietary OGAP® drug discovery platformFast...
Cell-Easy is pleased to welcome Mrs. Gisele Deblandre, formerly CSO at MaSTherCell, as Chief Scientific Officer
September 28, 2023 08:15 ET
|
CELL-EASY
Cell-Easy, a contract development and manufacturing organization (CDMO) in cell therapy, proudly announces the appointment of Mrs. Gisele Deblandre.